Invest in 5 new US stocks in the Cannabis industry

The consumption, legalisation and benefits of cannabis have become part of a global conversation, but another smoking hot topic is the investment potential in the marijuana-related companies involved in this new industry. Big companies and small, as well as those that provide supporting services into the Cannabis industry have seen huge growth spurts in the last few years, and piqued the interest of budding investors. Check out some of these stats in this Investopedia article on the Top Marijuana Stocks to Watch

In providing investors access to participate in this exciting area of the market with great ‘growth’ prospects, we have listed five (5) new US stocks which deal with the broader commercial world of Cannabis.

We've compiled some must-know info around these five stocks you can now purchase via your EasyEquities USD account:

New call-to-action

GW Pharmaceuticals
Originally a UK company, GW Pharmaceuticals is the first company to obtain FDA approval of cannabidiol, and successfully developed the world’s first prescription medicine derived from the cannabis plant. This chemical is now approved in numerous countries outside the United States, in the treatment of spasticity due to multiple sclerosis. They also develop a liquid formula of purified cannabidiol (CBD) for the treatment of seizures in rare and severe early-onset drug resistant epilepsy syndromes.

New call-to-action

Canopy Growth
This company was the first cannabis company in North America to be publicly traded. One of their subsidiaries, Tweed, was the first to introduce the now standard concept of Compassionate Pricing to make medical cannabis affordable for patients. They remain proud to campaign in support of a patient’s right to grow at home (and thus sustainably self-medicate) by selling wide variety of seeds in the legal Canadian Sector.

New call-to-action

Cronos Group
The group comprised of three subsidiaries, Peace Naturals, OGBC and WMMC. Peace Naturals has been growing quickly to meet the needs of patients across Canada and abroad. Their latest expansion includes one of the largest indoor, purpose-built facilities in the industry, as well as a custom-built extraction lab that will enable them to increase their supply without ever compromising their product quality. They believe in a Whole Health approach to wellness, which emphasises a patient’s diet and lifestyle, in addition to the use of medicinal cannabis as an adjunct therapy.

New call-to-action

Cara Therapeutics
CARA is a clinical-stage biotechnology company focused on developing and commercialising new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed and treated. Cara is developing a novel and proprietary class of product candidates that target the body’s peripheral nervous system. These products have demonstrated initial efficacy in patients with moderate-to-severe pain and pruritus (itch), without inducing many of the undesirable side effects typically associated with currently available pain and itch therapeutics.

New call-to-action

Tilray is a global leader in medical cannabis research, cultivation, processing and distribution. They inspire to lead, legitimise, and define the future of the industry by building the worlds most trusted cannabis company. A proud pioneer, they were the first GMP-Certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and research facilities on five continents.


Some Marijuana Did-You-Knows

Countries that allow the medical use of whole-plant cannabis include, Australia, Canada, Chile, Colombia, Germany, Greece, Israel, Italy, the Netherlands, Peru, Poland, The United Kingdom and Uruguay. In the United States, 31 states as well as the District of Columbia have legalised cannabis for medical purposes.

The broad range of medical applications include:

  • Chronic pain
  • Alzheimer’s disease applications
  • Parkinson’s disease moderation
  • Varied cancer applications
  • Control of epilepsy
  • Lung capacity issues
  • Improvement of appetite
  • Muscle spasms
  • Glaucoma treatment
  • Decreased anxiety
  • Arthritis relief

Probably the best known and widely researched effects of cannabis is around cancer treatment. Several studies by the American Cancer Society (2015) discovered that smoking marijuana can be helpful in treating nausea and vomiting from cancer chemotherapy. Some animal studies (Veterinarni Medicina, (2016) also suggest that certain cannabinoids may slow the growth, and reduce the spread, of some forms of cancer

Glioblastoma (GBM) is the most malignant brain tumour and one of the deadliest types of solid cancer overall. The National Centre for Biotechnology Information published a piece where the Frontiers in Molecular Neuroscience (2018) states “ Accumulating evidence indicates that cannabinoids have potent anti-tumor functions and might be used successfully in the treatment of GBM”  The International Journal of Oncology published a study last year indicating that cannabinoids successfully kill cancer cells, with benefits of use increasing when combined with chemotherapy.

Read more about the active ingredients in marijuana by clicking on the below.

New call-to-action


New call-to-action


Until next time 

Happy Investing! 

Any opinions, news, research, reports, analyses, prices, or other information contained within this research is provided by an employee of EasyEquities an authorised FSP (FSP no 22588) as general market commentary and does not constitute investment advice for the purposes of the Financial Advisory and Intermediary Services Act, 2002. First World Trader (Pty) Ltd t/a EasyEquities (“EasyEquities”) does not warrant the correctness, accuracy, timeliness, reliability or completeness of any information (i) contained within this research and (ii) received from third party data providers. You must rely solely upon your own judgment in all aspects of your investment and/or trading decisions and all investments and/or trades are made at your own risk. EasyEquities (including any of their employees) will not accept any liability for any direct or indirect loss or damage, including without limitation, any loss of profit, which may arise directly or indirectly from use of or reliance on the market commentary. The content contained within is subject to change at any time without notice.

Previous Blog

Next Blog

Let Us Help You, Help Yourself

From how-to’s to whos-whos you’ll find a bunch of interesting and helpful stuff in our collection of videos. Our knowledge base is jam packed with answers to all the questions you can think of.